The Role of p90 Ribosomal S6 Kinase (RSK) in Tyrosine Kinase Inhibitor (TKI)-Induced Cardiotoxicity
Date
2023-01-01Author
Suleiman, MunaAl Najjar, Afnan
Zakaria, Zain Z.
Ahmed, Rashid
Yalcin, Huseyin C.
Korashy, Hesham M.
Uddin, Shahab
Riaz, Sadaf
Abdulrahman, Nabeel
Mraiche, Fatima
...show more authors ...show less authors
Metadata
Show full item recordAbstract
Targeted therapy, such as tyrosine kinase inhibitors (TKIs), has been approved to manage various cancer types. However, TKI-induced cardiotoxicity is a limiting factor for their use. This issue has raised the need for investigating potential cardioprotective techniques to be combined with TKIs. Ribosomal S6-kinases (RSKs) are a downstream effector of the mitogen-activated-protein-kinase (MAPK) pathway; specific RSK isoforms, such as RSK1 and RSK2, have been expressed in cancer cells, in which they increase tumour proliferation. Selective targeting of those isoforms would result in tumour suppression. Moreover, activation of RSKs expressed in the heart has resulted in cardiac hypertrophy and arrhythmia; thus, inhibiting RSKs would result in cardio-protection. This review article presents an overview of the usefulness of RSK inhibitors that can be novel agents to be assessed in future research for their effect in reducing cancer proliferation, as well as protecting the heart from cardiotoxicity induced by TKIs. Graphical Abstract: [Figure not available: see fulltext.]
Collections
- Biomedical Research Center Research [709 items ]
- Biomedical Sciences [692 items ]
- Pharmacy Research [1234 items ]